Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics...
Global trade, energy transition, financial regulation, multinational corporations, and macroeconomic trends.
Categories
Recent Posts
- Another analyst has blunt message on Social Security and retirees
- Gold holds decline as Hormuz quagmire keeps inflation fear high
- President Trump interview: An hour in the Oval Office with the CEO-in-Chief
- Ryanair says flat fares likely amid lack of visibility – Daily Business
- AMD buys $6.5 million of surging tech stock